IQVIA Named Best Contract Research Organization Full-Service Provider in 2018 Scrip Awards
December 06 2018 - 8:00AM
Business Wire
IQVIA’s Innovative Technology, Advanced
Analytics and Industry Expertise Demonstrate the Value of Its CORE
to Industry Partners
IQVIA™ (NYSE:IQV) today announced that it was awarded the 2018
Scrip Award for Best Contract Research Organization — Full-Service
Provider. This marks the seventh time in the last 10 years that the
company has received this award.
“We are honored to receive this award which recognizes our
commitment to build strong, collaborative partnerships with our
clients using CORE-enabled solutions,” said Richard Staub,
president, Research & Development Solutions at IQVIA. “Using
our innovative technology, analytics-driven insights and deep
clinical expertise, we are proud to help our clients drive
healthcare innovations forward in novel ways.”
IQVIA’s approach to clinical development leverages real world
evidence-driven design capabilities to overcome the root causes of
trial inefficiencies that have plagued the industry for many years.
At the heart of IQVIA’s solutions is the IQVIA CORE™ which pairs
transformative technology and advanced analytics with IQVIA’s deep
therapeutic and scientific expertise to analyze a vast amount of
real-world data.
The Best Contract Research Organization — Full-Service Provider
award acknowledges the critical role that CROs play in drug
development. Nominees are judged on the quality of services and
relationships that they have built with clients and the innovative
patient recruitment strategies they have implemented.
An independent panel of 17 life sciences experts judged the
nominations, and the winners were announced at the 14th Annual
Scrip Awards Ceremony in London November 28. Hosted by Pharma
Intelligence, a top team of journalists, researchers and analysts,
the Scrip Awards recognize excellence within the biopharmaceutical
industry.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced
analytics, technology solutions and contract research services to
the life sciences industry. Formed through the merger of IMS Health
and Quintiles, IQVIA applies human data science — leveraging the
analytic rigor and clarity of data science to the ever-expanding
scope of human science — to enable companies to reimagine and
develop new approaches to clinical development and
commercialization, speed innovation and accelerate improvements in
healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers
unique and actionable insights at the intersection of large-scale
analytics, transformative technology and extensive domain
expertise, as well as execution capabilities. With more than 55,000
employees, IQVIA conducts operations in more than 100
countries.
IQVIA is a global leader in protecting individual patient
privacy. The company uses a wide variety of privacy-enhancing
technologies and safeguards to protect individual privacy while
generating and analyzing the information that helps their customers
drive human health outcomes forward. IQVIA’s insights and execution
capabilities help biotech, medical device and pharmaceutical
companies, medical researchers, government agencies, payers and
other healthcare stakeholders tap into a deeper understanding of
diseases, human behaviors and scientific advances, in an effort to
advance their path toward cures. To learn more, visit
www.iqvia.com.
Click here to subscribe to Mobile Alerts for IQVIA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181206005424/en/
Tor Constantino, IQVIA Media Relations
(tor.constantino@iqvia.com)+1.484.567.6732Andrew Markwick, IQVIA
Investor Relations (andrew.markwick@iqvia.com)+1.973.257.7144
IQVIA (NYSE:IQV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IQVIA (NYSE:IQV)
Historical Stock Chart
From Jul 2023 to Jul 2024